The Push to Grow BD Medical Devices
Executive SummaryBecton Dickinson's strength in medical devices has always been building large market shares in high volume lines and then managing for profitability through more efficient manufacturing. But the company has begun an aggressive growth campaign just as its core businesses have begun to stagnate. Customer consolidation and more aggressive competition is leading this cautious company to become a risk-taker.
You may also be interested in...
A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies.
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.